SCINAI IMMUNOTHERAPEUTICS LT (SCNI)
US09073Q3039 - ADR
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 1.03M | 4.87M | 14.07M | 17.41M | 2.93M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | N/A | |||
| Receivables | 120.00K | N/A | N/A | 326.00K | 375.00K | |||
| Other Current Assets | 465.00K | 577.00K | 295.00K | N/A | N/A | |||
| Total Current Assets | 1.62M | 5.45M | 14.37M | 17.73M | 3.31M | |||
| Non-Current Assets | ||||||||
| PPE Net | 10.64M | 12.03M | 12.70M | 14.21M | 14.27M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | N/A | N/A | N/A | 143.00K | 147.00K | |||
| Total Non-Current Assets | 10.64M | 12.03M | 12.70M | 14.35M | 14.42M | |||
| TOTAL ASSETS | 12.26M | 17.47M | 27.07M | 32.08M | 17.73M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 18.82M | |||
| Accrued Expenses | 364.00K | 1.25M | 1.62M | 249.00K | 204.00K | |||
| Accounts Payable | 430.00K | 535.00K | 716.00K | 2.07M | 970.00K | |||
| Other Current Liabilities | 598.00K | N/A | N/A | N/A | N/A | |||
| Total Current Liabilities | 1.39M | 1.78M | 2.34M | 2.32M | 19.99M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 280.00K | 19.37M | 20.08M | 22.21M | 1.90M | |||
| Other Non-Current Liabilities | 586.00K | 893.00K | 6.41M | 31.00K | 383.00K | |||
| Total Non-Current Liabilities | 866.00K | 20.26M | 26.49M | 22.24M | 2.28M | |||
| TOTAL LIABILITIES | 2.26M | 22.04M | 28.83M | 24.57M | 22.27M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -115.31M | -122.33M | -115.83M | -117.49M | -101.16M | |||
| Additional Paid In Capital | 121.42M | 119.51M | 116.08M | 125.00M | 96.61M | |||
| Common Shares | 5.63M | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -1.74M | -1.74M | -2.01M | N/A | N/A | |||
| Shares Outstanding | 862.54K | 469.48K | 250.09K | 18.68K | 11.66K | |||
| Tangible Book Value per Share | 0.00 | -0.00 | -0.00 | 0.10 | -0.10 | |||
| Total Shareholders' Equity | 10.00M | -4.57M | -1.76M | 7.51M | -4.55M | |||
| TOTAL LIABILITIES AND EQUITY | 12.26M | 17.47M | 27.07M | 32.08M | 17.73M | |||
| Statistics | ||||||||
| Debt/Equity | 0.03 | -4.24 | -11.41 | 2.96 | -4.56 | |||
| Current Ratio | 1.16 | 3.06 | 6.15 | 7.64 | 0.17 | |||
| Return On Assets (ROA) | 20.69% | -37.20% | -21.41% | -38.58% | -7.31% | |||
| Return On Equity (ROE) | 25.36% | N/A | N/A | -164.70% | N/A | |||
| Return On Invested Capital (ROIC) | N/A | N/A | N/A | N/A | 10.18% | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | N/A | N/A | 12.38% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | N/A | N/A | 12.38% | |||
All data in USD , ROIC based on taxRate of 0.21